Phase II study of epirubicin in advanced adenocarcinoma of the pancreas
- 1 February 1985
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 21 (2), 191-194
- https://doi.org/10.1016/0277-5379(85)90172-5
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group studyCancer, 1983
- 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical dataCancer Treatment Reviews, 1983
- Phase II Trial of Combination Chemotherapy for Pancreatic Cancer with 5-Fluorouracil, Mitomycin C, and HexamethylmelamineOncology, 1983
- Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinomaCancer, 1982
- 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreasCancer, 1980
- TREATMENT OF METASTATIC PANCREATIC AND GASTRIC ADENOCARCINOMAS WITH 5-FLUOROURACIL, ADRIAMYCIN, AND MITOMYCIN-C (FAM)1979
- Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group reportCancer, 1978
- Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancerCancer, 1978
- A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancerCancer, 1974